顶部logo
顶部logo
more_1

home

ホーム > レポート一覧 > グローバル組換えタンパク質ペプチド医薬品市場規模、主要企業シェア、ランキング分析レポート【2026年版】

グローバル組換えタンパク質ペプチド医薬品市場規模、主要企業シェア、ランキング分析レポート【2026年版】

Recombinant Protein Peptide Drug - Global Top Players Market Share and Ranking 2026
  • レポートID：
    224051
  • 発表時期：
    2026-03-03
  • レポート形式：
    PDF
  • 産業カテゴリー：
    薬品及びサプリメント
  • レポート言語：
    英語、日本語
  • ページ数：
    109
  • 発行会社（調査会社）：
    YHResearch
title

言語とエディションの価格

  • 英語版
  • 日本語版
  • 英語と日本語版

個人版詳細

マルチユーザー版詳細

企業版詳細

  • 英語版
  • 日本語版
  • 英語と日本語版

価格表記: USDを日本円(税抜)に換算，本日の銀行送金レート: 1USD=162.40円。

※米ドル表示価格+10％消費税。

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

title

レポートの概要

本報告書は、世界の組換えタンパク質ペプチド医薬品市場について包括的な分析を行い、市場全体の動向を明らかにすることを目的としています。総販売数量、売上高、価格動向に加え、主要企業の市場シェアおよび順位を整理し、市場構造を多角的に把握します。さらに、地域・国別、製品タイプ別、用途分野別などの観点から組換えタンパク質ペプチド医薬品市場を分析し、需要構造と成長特性を明確化します。
組換えタンパク質ペプチド医薬品市場の規模、推定値および予測は、2025年を基準年とし、2021年から2032年までの期間における販売数量および売上高に基づいて提示しています。定量分析と定性分析を組み合わせることで、ビジネスおよび成長戦略を検討し、市場競争環境を評価し、企業の市場ポジションを把握した上で、組換えタンパク質ペプチド医薬品に関する的確な意思決定を行うための実践的なインサイトを提供します。
 主要組換えタンパク質ペプチド医薬品市場の統計
2025年世界市場規模：2693百万米ドル
2026年世界市場規模：2902百万米ドル
2032年予測市場規模：4623百万米ドル
2026–2032年予測期間CAGR：8.1%
本レポートは組換えタンパク質ペプチド医薬品市場の中長期的な成長動向を定量分析および定性分析の両面から体系的に整理しています。 
【市場セグメンテーション】
主要企業・競争環境
組換えタンパク質ペプチド医薬品市場の主要企業には以下が含まれます：
Roche
Novartis
Amgen
Genentech
Eli Lilly and Company
Sanofi
Biogen
AstraZeneca 

製品別
Recombinant Protein Hormone
Peptide Drugs
Recombinant Vaccine Protein
Others 

アプリケーション別
Hospital
Clinic 

レポート対象地域
北米：アメリカ、カナダ、その他
アジア太平洋：中国、日本、韓国、東南アジア、インド、オーストラリア、その他
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、オランダ、北欧諸国、その他
ラテンアメリカ：メキシコ、ブラジル、その他
中東・アフリカ：トルコ、サウジアラビア、UAE、その他

レポート構成（章別概要）
第1章｜市場概要と成長展望
組換えタンパク質ペプチド医薬品市場の全体像を整理し、市場規模、売上予測、価格推移を体系的に解説します。同時に成長要因、市場機会、業界課題、リスク要因を分析し、中長期的な市場展望を提示します
第2章｜主要企業の競争分析
組換えタンパク質ペプチド医薬品市場における主要プレイヤー（トップ5社・トップ10社）を対象に、売上高、製造拠点、製品構成、価格戦略、販売量、市場シェアを多面的に分析し、競争構造を明確化します
第3章｜製品カテゴリ別市場動向
製品タイプ別に組換えタンパク質ペプチド医薬品市場を分類し、売上高、市場シェア、販売量、価格動向を分析します。成長性の高い製品分野と市場構造の変化を明らかにします
第4章｜用途別市場動向
用途別に組換えタンパク質ペプチド医薬品市場規模、売上高、市場シェア、販売量、価格推移を整理し、業界別の需要動向と成長ポテンシャルを分析します
第5章｜地域別市場分析
地域別の市場成長率、販売量、売上高を詳細に分析し、組換えタンパク質ペプチド医薬品市場の地理的需要構造を可視化します。各地域の市場規模推移と将来の成長余地を評価します
第6章｜国別市場動向
主要国・地域ごとに、組換えタンパク質ペプチド医薬品市場の販売量、売上高、成長要因、政策・規制環境、競争特性を整理し、国別市場の特徴を明確にします
第7章｜主要企業プロファイル
組換えタンパク質ペプチド医薬品市場を牽引する主要企業について、売上高、販売量、価格動向、粗利益率、製品ポートフォリオ、最新の戦略動向を詳細に解説します
第8章｜バリューチェーンと市場構造分析
業界全体のサプライチェーンを上流から下流まで整理し、コスト構造や流通モデルの動向を分析します
第9章｜調査結果
調査結果を総括し、市場全体のトレンド、今後の成長機会、潜在的リスク、戦略的な洞察を提示します
第10章｜付録（調査手法・データソース）
調査設計、分析手法、使用データソースの詳細を明示し、レポートの信頼性と透明性を担保します

本レポートの要点と洞察
 組換えタンパク質ペプチド医薬品市場の全体像と成長見通し
組換えタンパク質ペプチド医薬品市場の規模変化の傾向、成長予測及び需要動向を体系的に整理いたします。2021年から2025年までの実績データに基づき、2032年までの中長期予測を提示し、市場の拡大速度と成長潜在力を明らかにします。同時に、最近の関税調整措置など各国の政策動向を踏まえ、多角的にグローバル経済環境が組換えタンパク質ペプチド医薬品市場に与える影響を分析いたします
 市場環境の構成要素とマクロトレンド
組換えタンパク質ペプチド医薬品産業を取り巻く市場環境について、需要構造の変化、政策対応、技術革新の進展といった主要要因を整理します。特に、国際貿易政策や関税政策の変化が企業戦略や価格形成に及ぼす影響、サプライチェーン再編の動きと事業運営への波及効果を明確化し、市場環境の全体像を包括的に提示します
 競争構造と主要企業の動向分析
組換えタンパク質ペプチド医薬品市場における主要企業の売上規模、市場シェア、競争ポジションを整理し、競争構造の特徴を分析します。各社の競争戦略、事業拡大の方向性、新製品・新技術の投入動向を通じて、技術革新が市場競争に与える影響と競争環境の変化を解読します
 競争環境と事業動向の把握
製品タイプ別、用途別、地域・国別の観点から組換えタンパク質ペプチド医薬品市場のセグメント構造を整理します。各地域の需要構成と成長特性を比較分析し、各細分領域が市場全体の成長に与える貢献度と相互関連性を明確にします
 成長要因・課題・リスクの分析
組換えタンパク質ペプチド医薬品市場の成長を支える主要ドライバーを整理するとともに、業界特有の課題や潜在的リスクを分析します。原材料調達、供給システム、事業運営における不確実性を踏まえ、サプライチェーン及び事業レジリエンス強化の方向性についても考察します
 将来トレンドと市場展望
組換えタンパク質ペプチド医薬品市場の中長期的な成長トレンドと将来の発展シナリオを提示します。持続的成長を実現するための重要な成功要因を整理し、今後の市場参入企業や既存プレイヤーの戦略的意思決定に参考となる視点を提供いたします
title

Description

According to YH Research, the global market for Recombinant Protein Peptide Drug should grow from US$ 2693 million in 2025 to US$ 4623 million by 2032, with a CAGR of 8.1% for the period of 2026-2032.

The strategic recalibration of 2025 U.S. tariff mechanisms is redefining global economic governance norms. This study deciphers the transmission mechanisms of tariff escalation pathways and global policy responses on corporate investment strategies, regional trade networks, and critical material supply architectures.
Recombinant protein and peptide drugs are a type of biological agents produced by genetic engineering technology, whose structure and function have been modified to meet specific therapeutic needs. These drugs have achieved remarkable success in the medical field and are widely used in cancer treatment, immune diseases, metabolic diseases and other fields. With the development of precision medicine, future recombinant protein and peptide drugs will be more individualized, with customized treatments based on the patient"s genotype, phenotype and biological characteristics.

This report studies and analyses global Recombinant Protein Peptide Drug status and future trends, helps the client to determine the Recombinant Protein Peptide Drug market size of the total market opportunity by Type, by Application, by company, and by region & country. This report is a detailed and comprehensive analysis of the world market for Recombinant Protein Peptide Drug, and provides market size (in K Units & US$ million) and Year-over-Year growth, considering 2025 as the base year.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

To assess the competitive environment within the market including supplier revenue, market share, and company profiles.

Highlights
(1) Global Recombinant Protein Peptide Drug market size, history data 2021-2025, and forecast data 2026-2032, (US$ million) & (K Units)
(2) Global Recombinant Protein Peptide Drug sales, revenue, price by company, market share and industry ranking 2021-2026, (US$ million) & (K Units)
(3) Japan Recombinant Protein Peptide Drug sales, revenue, price by company, market share and industry ranking 2021-2026, (US$ million) & (K Units)
(4) Global Recombinant Protein Peptide Drug key consuming regions, consumption quantity, consumption value and demand structure
(5) Global Recombinant Protein Peptide Drug key producing regions, capacity, production, and year over year growth
(6) Recombinant Protein Peptide Drug industry chains, upstream, midstream and downstream
Market segment by players, this report covers
    Roche
    Novartis
    Amgen
    Genentech
    Eli Lilly and Company
    Sanofi
    Biogen
    AstraZeneca

Market segment by Type, covers
    Recombinant Protein Hormone
    Peptide Drugs
    Recombinant Vaccine Protein
    Others

Market segment by Application, can be divided into
    Hospital
    Clinic

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Report Includes:
Chapter 1: to describe Recombinant Protein Peptide Drug product scope, global sales quantity, value and average price, Japan sales quantity, value and average price, development opportunities, challenges, trends, and policies
Chapter 2: Global Recombinant Protein Peptide Drug market share and ranking of major manufacturers, sales quantity, revenue, average price, 2021-2026
Chapter 3: Japan Recombinant Protein Peptide Drug market share and ranking of major manufacturers, sales quantity, revenue, average price, 2021-2026
Chapter 4: Global key producing regions of Recombinant Protein Peptide Drug, percent & CAGR, 2021-2032
Chapter 5: Recombinant Protein Peptide Drug industry chain, upstream, medium-stream, and downstream
Chapter 6: Segment by Type, sales quantity, average price, consumption value, percent & CAGR, 2021-2032
Chapter 7: Segment by Application, sales quantity, average price, consumption value, percent & CAGR, 2021-2032
Chapter 8: Segment in regional level, sales quantity, average price, consumption value, percent & CAGR, 2021-2032
Chapter 9: Segment in country level, sales quantity, average price, consumption value, percent & CAGR, 2021-2032
Chapter 10: Company profile, introducing the basic situation of the main companies in the market in detail, including product specifications, application, recent development, sales quantity, average price, revenue, gross margin
Chapter 11: Conclusions
title

Table of Contents

1 Market Overview
    1.1 Recombinant Protein Peptide Drug Definition
    1.2 Global Recombinant Protein Peptide Drug Market Size and Forecast
        1.2.1 By Consumption Value, Global Recombinant Protein Peptide Drug Market Size, 2021-2032
        1.2.2 By Sales Quantity, Global Recombinant Protein Peptide Drug Market Size, 2021-2032
        1.2.3 Global Recombinant Protein Peptide Drug Average Selling Price (ASP), 2021-2032
    1.3 Japan Recombinant Protein Peptide Drug Market Size and Forecast
        1.3.1 By Consumption Value, Japan Recombinant Protein Peptide Drug Market Size, 2021-2032
        1.3.2 By Sales Quantity, Japan Recombinant Protein Peptide Drug Market Size, 2021-2032
        1.3.3 Japan Recombinant Protein Peptide Drug Average Selling Price (ASP), 2021-2032
    1.4 Share of Japan Recombinant Protein Peptide Drug Market with Respect to the Global Market
        1.4.1 By Consumption Value, Japan Recombinant Protein Peptide Drug Market Share in Global, 2021-2032
        1.4.2 By Sales Quantity, Japan Recombinant Protein Peptide Drug Market Share in Global, 2021-2032
        1.4.3 Recombinant Protein Peptide Drug Market Size: Japan VS Global, 2021-2032
    1.5 Recombinant Protein Peptide Drug Market Dynamics
        1.5.1 Recombinant Protein Peptide Drug Market Drivers
        1.5.2 Recombinant Protein Peptide Drug Market Restraints
        1.5.3 Recombinant Protein Peptide Drug Industry Trends
        1.5.4 Recombinant Protein Peptide Drug Industry Policy
2 Global Leading Manufacturers and Market Share
    2.1 By Revenue of Recombinant Protein Peptide Drug, Global Market Share by Company, 2021-2026
    2.2 By Sales Quantity of Recombinant Protein Peptide Drug, Global Market Share by Company, 2021-2026
    2.3 Recombinant Protein Peptide Drug Average Selling Price (ASP) by Company, 2021-2026
    2.4 Global Recombinant Protein Peptide Drug Participants, Market Position (Tier 1, Tier 2, and Tier 3)
    2.5 Global Recombinant Protein Peptide Drug Concentration Ratio
    2.6 Global Recombinant Protein Peptide Drug Mergers & Acquisitions, Expansion Plans
    2.7 Global Recombinant Protein Peptide Drug Manufacturers Product Type
    2.8 Head Office and Recombinant Protein Peptide Drug Production Site of Key Manufacturer
    2.9 Recombinant Protein Peptide Drug Capacity of Major Manufacturers and Future Plan
3 Japan Leading Manufacturers and Market Share
    3.1 By Revenue of Recombinant Protein Peptide Drug, Japan Market Share by Company, 2021-2026
    3.2 By Sales Quantity of Recombinant Protein Peptide Drug, Japan Market Share by Company, 2021-2026
    3.3 Japan Recombinant Protein Peptide Drug Recombinant Protein Peptide Drug Participants, Market Position (Tier 1, Tier 2, and Tier 3)
4 Global Producing Regions
    4.1 Global Recombinant Protein Peptide Drug Capacity, Output and Capacity Utilization, 2021-2032
    4.2 Global Recombinant Protein Peptide Drug Capacity by Region
    4.3 Global Recombinant Protein Peptide Drug Production & Forecast by Region, 2021 VS 2025 VS 2032
    4.4 Global Recombinant Protein Peptide Drug Production by Region, 2021-2032
    4.5 Global Recombinant Protein Peptide Drug Production Market Share & Forecast by Region, 2021-2032
5 Industry Chain Analysis
    5.1 Recombinant Protein Peptide Drug Industry Chain
    5.2 Recombinant Protein Peptide Drug Upstream Analysis
        5.2.1 Recombinant Protein Peptide Drug Core Raw Materials
        5.2.2 Main Manufacturers of Recombinant Protein Peptide Drug Core Raw Materials
    5.3 Midstream Analysis
    5.4 Downstream Analysis
    5.5 Recombinant Protein Peptide Drug Production Mode
    5.6 Recombinant Protein Peptide Drug Procurement Model
    5.7 Recombinant Protein Peptide Drug Industry Sales Model and Sales Channels
        5.7.1 Recombinant Protein Peptide Drug Sales Model
        5.7.2 Recombinant Protein Peptide Drug Typical Distributors
6 Sights by Type
    6.1 Recombinant Protein Peptide Drug Classification by Type
        6.1.1 Recombinant Protein Hormone
        6.1.2 Peptide Drugs
        6.1.3 Recombinant Vaccine Protein
        6.1.4 Others
    6.2 by Type, Global Recombinant Protein Peptide Drug Consumption Value & CAGR, 2021 VS 2025 VS 2032
    6.3 by Type, Global Recombinant Protein Peptide Drug Consumption Value, 2021-2032
    6.4 by Type, Global Recombinant Protein Peptide Drug Sales Quantity, 2021-2032
    6.5 by Type, Global Recombinant Protein Peptide Drug Average Selling Price (ASP), 2021-2032
7 Sights by Application
    7.1 Recombinant Protein Peptide Drug Segment by Application
        7.1.1 Hospital
        7.1.2 Clinic
    7.2 by Application, Global Recombinant Protein Peptide Drug Consumption Value & CAGR, 2021 VS 2025 VS 2032
    7.3 by Application, Global Recombinant Protein Peptide Drug Consumption Value, 2021-2032
    7.4 by Application, Global Recombinant Protein Peptide Drug Sales Quantity, 2021-2032
    7.5 by Application, Global Recombinant Protein Peptide Drug Price, 2021-2032
8 Sales Sights by Region
    8.1 By Region, Global Recombinant Protein Peptide Drug Consumption Value, 2021 VS 2025 VS 2032
    8.2 By Region, Global Recombinant Protein Peptide Drug Consumption Value, 2021-2032
    8.3 By Region, Global Recombinant Protein Peptide Drug Sales Quantity, 2021-2032
    8.4 North America
        8.4.1 North America Recombinant Protein Peptide Drug Market Size & Forecasts, 2021-2032
        8.4.2 By Country, North America Recombinant Protein Peptide Drug Market Size Market Share
    8.5 Europe
        8.5.1 Europe Recombinant Protein Peptide Drug Market Size & Forecasts, 2021-2032
        8.5.2 By Country, Europe Recombinant Protein Peptide Drug Market Size Market Share
    8.6 Asia Pacific
        8.6.1 Asia Pacific Recombinant Protein Peptide Drug Market Size & Forecasts, 2021-2032
        8.6.2 By Country/Region, Asia Pacific Recombinant Protein Peptide Drug Market Size Market Share
    8.7 South America
        8.7.1 South America Recombinant Protein Peptide Drug Market Size & Forecasts, 2021-2032
        8.7.2 By Country, South America Recombinant Protein Peptide Drug Market Size Market Share
    8.8 Middle East & Africa
9 Sales Sights by Country Level
    9.1 By Country, Global Recombinant Protein Peptide Drug Market Size & CAGR, 2021 VS 2025 VS 2032
    9.2 By Country, Global Recombinant Protein Peptide Drug Consumption Value, 2021-2032
    9.3 By Country, Global Recombinant Protein Peptide Drug Sales Quantity, 2021-2032
    9.4 United States
        9.4.1 United States Recombinant Protein Peptide Drug Market Size, 2021-2032
        9.4.2 by Type, United States Recombinant Protein Peptide Drug Sales Quantity Market Share, 2025 VS 2032
        9.4.3 by Application, United States Recombinant Protein Peptide Drug Sales Quantity Market Share, 2025 VS 2032
    9.5 Europe
        9.5.1 Europe Recombinant Protein Peptide Drug Market Size, 2021-2032
        9.5.2 by Type, Europe Recombinant Protein Peptide Drug Sales Quantity Market Share, 2025 VS 2032
        9.5.3 by Application, Europe Recombinant Protein Peptide Drug Sales Quantity Market Share, 2025 VS 2032
    9.6 China
        9.6.1 China Recombinant Protein Peptide Drug Market Size, 2021-2032
        9.6.2 by Type, China Recombinant Protein Peptide Drug Sales Quantity Market Share, 2025 VS 2032
        9.6.3 by Application, China Recombinant Protein Peptide Drug Sales Quantity Market Share, 2025 VS 2032
    9.7 Japan
        9.7.1 Japan Recombinant Protein Peptide Drug Market Size, 2021-2032
        9.7.2 by Type, Japan Recombinant Protein Peptide Drug Sales Quantity Market Share, 2025 VS 2032
        9.7.3 by Application, Japan Recombinant Protein Peptide Drug Sales Quantity Market Share, 2025 VS 2032
    9.8 South Korea
        9.8.1 South Korea Recombinant Protein Peptide Drug Market Size, 2021-2032
        9.8.2 by Type, South Korea Recombinant Protein Peptide Drug Sales Quantity Market Share, 2025 VS 2032
        9.8.3 by Application, South Korea Recombinant Protein Peptide Drug Sales Quantity Market Share, 2025 VS 2032
    9.9 Southeast Asia
        9.9.1 Southeast Asia Recombinant Protein Peptide Drug Market Size, 2021-2032
        9.9.2 by Type, Southeast Asia Recombinant Protein Peptide Drug Sales Quantity Market Share, 2025 VS 2032
        9.9.3 by Application, Southeast Asia Recombinant Protein Peptide Drug Sales Quantity Market Share, 2025 VS 2032
    9.10 India
        9.10.1 India Recombinant Protein Peptide Drug Market Size, 2021-2032
        9.10.2 by Type, India Recombinant Protein Peptide Drug Sales Quantity Market Share, 2025 VS 2032
        9.10.3 by Application, India Recombinant Protein Peptide Drug Sales Quantity Market Share, 2025 VS 2032
    9.11 Middle East & Africa
        9.11.1 Middle East & Africa Recombinant Protein Peptide Drug Market Size, 2021-2032
        9.11.2 by Type, Middle East & Africa Recombinant Protein Peptide Drug Sales Quantity Market Share, 2025 VS 2032
        9.11.3 by Application, Middle East & Africa Recombinant Protein Peptide Drug Sales Quantity Market Share, 2025 VS 2032
10 Manufacturers Profile
    10.1 Roche
        10.1.1 Roche Company Information, Head Office, Market Area, and Industry Position
        10.1.2 Roche Recombinant Protein Peptide Drug Models, Specifications, and Application
        10.1.3 Roche Recombinant Protein Peptide Drug Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
        10.1.4 Roche Company Profile and Main Business
        10.1.5 Roche Recent Developments
    10.2 Novartis
        10.2.1 Novartis Company Information, Head Office, Market Area, and Industry Position
        10.2.2 Novartis Recombinant Protein Peptide Drug Models, Specifications, and Application
        10.2.3 Novartis Recombinant Protein Peptide Drug Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
        10.2.4 Novartis Company Profile and Main Business
        10.2.5 Novartis Recent Developments
    10.3 Amgen
        10.3.1 Amgen Company Information, Head Office, Market Area, and Industry Position
        10.3.2 Amgen Recombinant Protein Peptide Drug Models, Specifications, and Application
        10.3.3 Amgen Recombinant Protein Peptide Drug Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
        10.3.4 Amgen Company Profile and Main Business
        10.3.5 Amgen Recent Developments
    10.4 Genentech
        10.4.1 Genentech Company Information, Head Office, Market Area, and Industry Position
        10.4.2 Genentech Recombinant Protein Peptide Drug Models, Specifications, and Application
        10.4.3 Genentech Recombinant Protein Peptide Drug Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
        10.4.4 Genentech Company Profile and Main Business
        10.4.5 Genentech Recent Developments
    10.5 Eli Lilly and Company
        10.5.1 Eli Lilly and Company Company Information, Head Office, Market Area, and Industry Position
        10.5.2 Eli Lilly and Company Recombinant Protein Peptide Drug Models, Specifications, and Application
        10.5.3 Eli Lilly and Company Recombinant Protein Peptide Drug Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
        10.5.4 Eli Lilly and Company Company Profile and Main Business
        10.5.5 Eli Lilly and Company Recent Developments
    10.6 Sanofi
        10.6.1 Sanofi Company Information, Head Office, Market Area, and Industry Position
        10.6.2 Sanofi Recombinant Protein Peptide Drug Models, Specifications, and Application
        10.6.3 Sanofi Recombinant Protein Peptide Drug Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
        10.6.4 Sanofi Company Profile and Main Business
        10.6.5 Sanofi Recent Developments
    10.7 Biogen
        10.7.1 Biogen Company Information, Head Office, Market Area, and Industry Position
        10.7.2 Biogen Recombinant Protein Peptide Drug Models, Specifications, and Application
        10.7.3 Biogen Recombinant Protein Peptide Drug Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
        10.7.4 Biogen Company Profile and Main Business
        10.7.5 Biogen Recent Developments
    10.8 AstraZeneca
        10.8.1 AstraZeneca Company Information, Head Office, Market Area, and Industry Position
        10.8.2 AstraZeneca Recombinant Protein Peptide Drug Models, Specifications, and Application
        10.8.3 AstraZeneca Recombinant Protein Peptide Drug Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
        10.8.4 AstraZeneca Company Profile and Main Business
        10.8.5 AstraZeneca Recent Developments
11 Conclusion
12 Appendix
    12.1 Research Methodology
    12.2 Data Source
        12.2.1 Secondary Sources
        12.2.2 Primary Sources
    12.3 Market Estimation Model
    12.4 Disclaimer
title

Table of Figures

List of Tables
 Table 1. Recombinant Protein Peptide Drug Consumption Value & CAGR: Japan VS Global, 2021-2032, US$ Million
 Table 2. Recombinant Protein Peptide Drug Market Restraints
 Table 3. Recombinant Protein Peptide Drug Market Trends
 Table 4. Recombinant Protein Peptide Drug Industry Policy
 Table 5. Global Recombinant Protein Peptide Drug Revenue by Company, 2021-2026, US$ million, Ranked Based on Revenue in 2025
 Table 6. Global Recombinant Protein Peptide Drug Revenue Share by Company, 2021-2026, Ranked by Data of 2025
 Table 7. Global Recombinant Protein Peptide Drug Sales Quantity by Company, (2021-2026) & (K Units), Ranked Based on Sales in 2025
 Table 8. Global Recombinant Protein Peptide Drug Sales Quantity Market Share by Company, 2021-2026, Ranked by Data of 2025
 Table 9. Global Recombinant Protein Peptide Drug Average Selling Price (ASP) by Company, (2021-2026) & (US$/Unit)
 Table 10. Global Recombinant Protein Peptide Drug Manufacturers Market Concentration Ratio (CR3 and HHI)
 Table 11. Global Recombinant Protein Peptide Drug Mergers & Acquisitions, Expansion Plans
 Table 12. Global Recombinant Protein Peptide Drug Manufacturers Product Type
 Table 13. Head Office and Recombinant Protein Peptide Drug Production Site of Key Manufacturer
 Table 14. Recombinant Protein Peptide Drug Capacity of Major Manufacturers and Future Plan
 Table 15. Japan Recombinant Protein Peptide Drug Revenue by Company, 2021-2026, US$ million, Ranked Based on Revenue in 2025
 Table 16. Japan Recombinant Protein Peptide Drug Revenue Share by Company, 2021-2026, Ranked by Data of 2025
 Table 17. Japan Recombinant Protein Peptide Drug Sales Quantity by Company, (2021-2026) & (K Units), Ranked Based on Sales in 2025
 Table 18. Japan Recombinant Protein Peptide Drug Sales Quantity Market Share by Company, 2021-2026, Ranked by Data of 2025
 Table 19. Global Recombinant Protein Peptide Drug Production & Forecast by Region, 2021 VS 2025 VS 2032, (K Units)
 Table 20. Global Recombinant Protein Peptide Drug Production by Region, 2021-2026, (K Units)
 Table 21. Global Recombinant Protein Peptide Drug Production Forecast by Region, 2027-2032, (K Units)
 Table 22. Global Key Players of Recombinant Protein Peptide Drug Upstream (Raw Materials)
 Table 23. Global Recombinant Protein Peptide Drug Typical Customers
 Table 24. Recombinant Protein Peptide Drug Typical Distributors
 Table 25. by Type, Global Recombinant Protein Peptide Drug Consumption Value & CAGR, 2021 VS 2025 VS 2032, US$ Million
 Table 26. by Application, Global Recombinant Protein Peptide Drug Consumption Value & CAGR, 2021 VS 2025 VS 2032, US$ Million
 Table 27. By Region, Global Recombinant Protein Peptide Drug Consumption Value, 2021 VS 2025 VS 2032, US$ Million
 Table 28. By Region, Global Recombinant Protein Peptide Drug Consumption Value, 2021-2032, US$ Million
 Table 29. By Region, Global Recombinant Protein Peptide Drug Sales Quantity, 2021-2032, (K Units)
 Table 30. By Country, Global Recombinant Protein Peptide Drug Consumption Value & CAGR, 2021 VS 2025 VS 2032, US$ Million
 Table 31. By Country, Global Recombinant Protein Peptide Drug Consumption Value, 2021-2032, US$ Million
 Table 32. By Country, Global Recombinant Protein Peptide Drug Consumption Value Market Share, 2021-2032
 Table 33. By Country, Global Recombinant Protein Peptide Drug Sales Quantity, 2021-2032, (K Units)
 Table 34. By Country, Global Recombinant Protein Peptide Drug Sales Quantity Market Share, 2021-2032
 Table 35. Roche Company Information, Head Office, Market Area, and Industry Position
 Table 36. Roche Recombinant Protein Peptide Drug Models, Specifications, and Application
 Table 37. Roche Recombinant Protein Peptide Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2021-2026
 Table 38. Roche Company Profile and Main Business
 Table 39. Roche Recent Developments
 Table 40. Novartis Company Information, Head Office, Market Area, and Industry Position
 Table 41. Novartis Recombinant Protein Peptide Drug Models, Specifications, and Application
 Table 42. Novartis Recombinant Protein Peptide Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2021-2026
 Table 43. Novartis Company Profile and Main Business
 Table 44. Novartis Recent Developments
 Table 45. Amgen Company Information, Head Office, Market Area, and Industry Position
 Table 46. Amgen Recombinant Protein Peptide Drug Models, Specifications, and Application
 Table 47. Amgen Recombinant Protein Peptide Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2021-2026
 Table 48. Amgen Company Profile and Main Business
 Table 49. Amgen Recent Developments
 Table 50. Genentech Company Information, Head Office, Market Area, and Industry Position
 Table 51. Genentech Recombinant Protein Peptide Drug Models, Specifications, and Application
 Table 52. Genentech Recombinant Protein Peptide Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2021-2026
 Table 53. Genentech Company Profile and Main Business
 Table 54. Genentech Recent Developments
 Table 55. Eli Lilly and Company Company Information, Head Office, Market Area, and Industry Position
 Table 56. Eli Lilly and Company Recombinant Protein Peptide Drug Models, Specifications, and Application
 Table 57. Eli Lilly and Company Recombinant Protein Peptide Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2021-2026
 Table 58. Eli Lilly and Company Company Profile and Main Business
 Table 59. Eli Lilly and Company Recent Developments
 Table 60. Sanofi Company Information, Head Office, Market Area, and Industry Position
 Table 61. Sanofi Recombinant Protein Peptide Drug Models, Specifications, and Application
 Table 62. Sanofi Recombinant Protein Peptide Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2021-2026
 Table 63. Sanofi Company Profile and Main Business
 Table 64. Sanofi Recent Developments
 Table 65. Biogen Company Information, Head Office, Market Area, and Industry Position
 Table 66. Biogen Recombinant Protein Peptide Drug Models, Specifications, and Application
 Table 67. Biogen Recombinant Protein Peptide Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2021-2026
 Table 68. Biogen Company Profile and Main Business
 Table 69. Biogen Recent Developments
 Table 70. AstraZeneca Company Information, Head Office, Market Area, and Industry Position
 Table 71. AstraZeneca Recombinant Protein Peptide Drug Models, Specifications, and Application
 Table 72. AstraZeneca Recombinant Protein Peptide Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2021-2026
 Table 73. AstraZeneca Company Profile and Main Business
 Table 74. AstraZeneca Recent Developments


List of Figures
 Figure 1. Recombinant Protein Peptide Drug Picture
 Figure 2. Global Recombinant Protein Peptide Drug Consumption Value, (US$ million) & (2021-2032)
 Figure 3. Global Recombinant Protein Peptide Drug Sales Quantity, (K Units) & (2021-2032)
 Figure 4. Global Recombinant Protein Peptide Drug Average Selling Price (ASP), (2021-2032) & (US$/Unit)
 Figure 5. Japan Recombinant Protein Peptide Drug Consumption Value, (US$ million) & (2021-2032)
 Figure 6. Japan Recombinant Protein Peptide Drug Sales Quantity (K Units) & (2021-2032)
 Figure 7. Japan Recombinant Protein Peptide Drug Average Selling Price (ASP), (US$/Unit) & (2021-2032)
 Figure 8. By Consumption Value, Japan Recombinant Protein Peptide Drug Market Share of Global, 2021-2032
 Figure 9. By Sales Quantity, Japan Recombinant Protein Peptide Drug Market Share of Global, 2021-2032
 Figure 10. Global Recombinant Protein Peptide Drug Market Share by Company, (Tier 1, Tier 2, and Tier 3), 2025
 Figure 11. Japan Recombinant Protein Peptide Drug Key Participants, Market Share, 2025
 Figure 12. Global Recombinant Protein Peptide Drug Capacity, Production and Capacity Utilization, 2021-2032
 Figure 13. Global Recombinant Protein Peptide Drug Capacity Market Share by Region, 2025 VS 2032
 Figure 14. Global Recombinant Protein Peptide Drug Production Market Share & Forecast by Region, 2021-2032
 Figure 15. Recombinant Protein Peptide Drug Industry Chain
 Figure 16. Recombinant Protein Peptide Drug Procurement Model
 Figure 17. Recombinant Protein Peptide Drug Sales Model
 Figure 18. Recombinant Protein Peptide Drug Sales Channels, Direct Sales, and Distribution
 Figure 19. Recombinant Protein Hormone
 Figure 20. Peptide Drugs
 Figure 21. Recombinant Vaccine Protein
 Figure 22. Others
 Figure 23. by Type, Global Recombinant Protein Peptide Drug Consumption Value, 2021-2032, US$ Million
 Figure 24. by Type, Global Recombinant Protein Peptide Drug Consumption Value Market Share, 2021-2032
 Figure 25. by Type, Global Recombinant Protein Peptide Drug Sales Quantity, 2021-2032, (K Units)
 Figure 26. by Type, Global Recombinant Protein Peptide Drug Sales Quantity Market Share, 2021-2032
 Figure 27. by Type, Global Recombinant Protein Peptide Drug Average Selling Price (ASP), 2021-2032, (US$/Unit)
 Figure 28. Hospital
 Figure 29. Clinic
 Figure 30. by Application, Global Recombinant Protein Peptide Drug Consumption Value, 2021-2032, US$ Million
 Figure 31. by Application, Global Recombinant Protein Peptide Drug Revenue Market Share, 2021-2032
 Figure 32. by Application, Global Recombinant Protein Peptide Drug Sales Quantity, 2021-2032, (K Units)
 Figure 33. by Application, Global Recombinant Protein Peptide Drug Sales Quantity Market Share, 2021-2032
 Figure 34. by Application, Global Recombinant Protein Peptide Drug Price, 2021-2032, (US$/Unit)
 Figure 35. By Region, Global Recombinant Protein Peptide Drug Consumption Value Market Share, 2021-2032
 Figure 36. By Region, Global Recombinant Protein Peptide Drug Sales Quantity Market Share, 2021-2032
 Figure 37. North America Recombinant Protein Peptide Drug Consumption Value & Forecasts, 2021-2032, US$ Million
 Figure 38. By Country, North America Recombinant Protein Peptide Drug Consumption Value Market Share, 2025
 Figure 39. Europe Recombinant Protein Peptide Drug Consumption Value & Forecasts, 2021-2032, US$ Million
 Figure 40. By Country, Europe Recombinant Protein Peptide Drug Consumption Value Market Share, 2025
 Figure 41. Asia Pacific Recombinant Protein Peptide Drug Consumption Value & Forecasts, 2021-2032, US$ Million
 Figure 42. By Country/Region, Asia Pacific Recombinant Protein Peptide Drug Consumption Value Market Share, 2025
 Figure 43. South America Recombinant Protein Peptide Drug Consumption Value & Forecasts, 2021-2032, US$ Million
 Figure 44. By Country, South America Recombinant Protein Peptide Drug Consumption Value Market Share, 2025
 Figure 45. Middle East & Africa Recombinant Protein Peptide Drug Consumption Value & Forecasts, 2021-2032, US$ Million
 Figure 46. United States Recombinant Protein Peptide Drug Sales Quantity, 2021-2032, (K Units)
 Figure 47. by Type, United States Recombinant Protein Peptide Drug Sales Quantity Market Share, 2025 VS 2032
 Figure 48. by Application, United States Recombinant Protein Peptide Drug Sales Quantity Market Share, 2025 VS 2032
 Figure 49. Europe Recombinant Protein Peptide Drug Sales Quantity, 2021-2032, (K Units)
 Figure 50. by Type, Europe Recombinant Protein Peptide Drug Sales Quantity Market Share, 2025 VS 2032
 Figure 51. by Application, Europe Recombinant Protein Peptide Drug Sales Quantity Market Share, 2025 VS 2032
 Figure 52. China Recombinant Protein Peptide Drug Sales Quantity, 2021-2032, (K Units)
 Figure 53. by Type, China Recombinant Protein Peptide Drug Sales Quantity Market Share, 2025 VS 2032
 Figure 54. by Application, China Recombinant Protein Peptide Drug Sales Quantity Market Share, 2025 VS 2032
 Figure 55. Japan Recombinant Protein Peptide Drug Sales Quantity, 2021-2032, (K Units)
 Figure 56. by Type, Japan Recombinant Protein Peptide Drug Sales Quantity Market Share, 2025 VS 2032
 Figure 57. by Application, Japan Recombinant Protein Peptide Drug Sales Quantity Market Share, 2025 VS 2032
 Figure 58. South Korea Recombinant Protein Peptide Drug Sales Quantity, 2021-2032, (K Units)
 Figure 59. by Type, South Korea Recombinant Protein Peptide Drug Sales Quantity Market Share, 2025 VS 2032
 Figure 60. by Application, South Korea Recombinant Protein Peptide Drug Sales Quantity Market Share, 2025 VS 2032
 Figure 61. Southeast Asia Recombinant Protein Peptide Drug Sales Quantity, 2021-2032, (K Units)
 Figure 62. by Type, Southeast Asia Recombinant Protein Peptide Drug Sales Quantity Market Share, 2025 VS 2032
 Figure 63. by Application, Southeast Asia Recombinant Protein Peptide Drug Sales Quantity Market Share, 2025 VS 2032
 Figure 64. India Recombinant Protein Peptide Drug Sales Quantity, 2021-2032, (K Units)
 Figure 65. by Type, India Recombinant Protein Peptide Drug Sales Quantity Market Share, 2025 VS 2032
 Figure 66. by Application, India Recombinant Protein Peptide Drug Sales Quantity Market Share, 2025 VS 2032
 Figure 67. Middle East & Africa Recombinant Protein Peptide Drug Sales Quantity, 2021-2032, (K Units)
 Figure 68. by Type, Middle East & Africa Recombinant Protein Peptide Drug Sales Quantity Market Share, 2025 VS 2032
 Figure 69. by Application, Middle East & Africa Recombinant Protein Peptide Drug Sales Quantity Market Share, 2025 VS 2032
 Figure 70. Research Methodology
 Figure 71. Breakdown of Primary Interviews
 Figure 72. Bottom-up Approaches
 Figure 73. Top-down Approaches

お見積>

サンプルお申込み>

今すぐ購入>

PDFダウンロード>

当社から購入のメリット
  • jiantou

    多言語（英語、日本語）のサンプル提供

  • jiantou

    プロフェッショナルな日本語翻訳を提供

  • jiantou

    請求書、クレジットカードでのお支払いが可能です

  • jiantou

    必要なチャプターやカスタマイズされたレポートの注文が可能

  • jiantou

    購入後、アナリストに直接連絡することができます

購入方法
shunxu

  • 必要な言語とバージョンのレポート選択

  • レポート要件と見積もり依頼

  • 電子メールによる注文

  • レポートの入手（英語版は2～4営業日、日本語版は8～10営業日）

  • クレジットカード決済、オフライン振込に対応（後払い可）

※当サイトに掲載されていない海外調査報告書も当社経由でご購入いただけますので、お問い合わせください。

※市場調査レポートの購入や市場調査をご希望の場合は、実績と信頼のある株式会社市場調査センターにお任せください。

*フォーチュン500企業は当社と緊密な協力関係を確立しています

クライアント様（例）
ご利用ガイド
利用規約よくあるご質問プライバシーポリシー支払い方法と購入ガイド
お電話でのお問い合わせ
email050-5840-2692 日本
email0081-50-5840-2692 グローバル
9:00-18:00 (土日・祝日を除く)
底部logo
Copyright 2016-2026 Global Reports著作権所有